Patent intelligence · US
US 12384853
Anti-HER2/PD1 bispecific antibody
Anti-HER2/PD1 bispecific antibody
Patent details — US 12384853
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 12, 2025
- Expiration
- Aug 7, 2045
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
Quick answer
US 12384853 (Anti-HER2/PD1 bispecific antibody) is held by SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00
More from SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428432
Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
granted -
US 12428389
Diarylamide compound and application thereof
granted -
US 12324812
Glucopyranosyl derivatives and their uses
granted -
US 12319748
Antibody binding to human HER2 and preparation method and use thereof
granted -
US 12312348
RET inhibitors, pharmaceutical compositions and uses thereof
granted -
US 12269886
Tetravalent bispecific antibody against PD-1 and PD-L1
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted
Frequently asked questions
What is US patent 12384853?
US 12384853 (Anti-HER2/PD1 bispecific antibody) is held by SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.. Status: granted. Granted Aug 12, 2025. Expires Aug 7, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12384853?
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.
When does US 12384853 expire?
Our index shows an expiration date of Aug 7, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.